Covid Vaccine Information

Ivermectin Studies in Treatment of COVID-19 (SARS-CoV-2)

Ivermectin is currently being used in many countries around the world in order to treat and prevent COVID-19. Some of the places where there is country wide adoption includes Bangladesh, Belize, Bolivia, Bulgaria, Cambodia, Dominican Republic, Egypt, El Salvador, Guatemala, Hondurus, Lebanon, Nicaragua, Panama, Venezuela and Zimbabwe. It is actually currently used for nearly 23% of the world’s population.


A meta analysis of Ivermectin shows that the drug is clearly beneficial in prevention and treatment of SARS-CoV-2.

Treatment timeNumber of studies reporting positive effectsTotal number of studiesPercentage of studies reporting positive effectsProbability of an equal or greater percentage of positive results from an ineffective treatmentRandom effects meta-analysis results
Early treatment242788.9%1 in 41 thousand72% improvement
RR 0.28 [0.18‑0.45] p < 0.0001
Late treatment202290.9%1 in 17 thousand40% improvement
RR 0.60 [0.48‑0.76] p < 0.0001
Prophylaxis1414100%1 in 16 thousand86% improvement
RR 0.14 [0.08‑0.25] p < 0.0001
All studies586392.1%1 in 1 trillion68% improvement
RR 0.32 [0.25‑0.40] p < 0.0001

The following are a collection of studies from around the world involving Ivermectin.

  1. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial [Science Direct, August 2021]
  2. Ivermectin as a SARS-CoV-2 Pre-Exposure Prophylaxis Method in Healthcare Workers: A Propensity Score-Matched Retrospective Cohort Study [Cureus, August 2021]
  3. Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers [Cureus, August, 2021]
  4. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-BlindRandomized Placebo Controlled Trial in Eastern India [July 2021]
  5. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [Lancet, July 2021]
  6. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial [BMC Infectious Diseases, July 2021]
  7. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients [Science Direct, July 2021]
  8. Clinical, Biochemical and Molecular Evaluations of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper Respiratory Symptoms of Mild COVID-19 [Dove Press, June 2021]
  9. Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City [SOC ARXIV, June 2021]
  10. Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial [MedRxIv, May 2021]
  11. Cluster Randomized Trials – Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers [Research Square, May 2021]
  12. Potential use of azithromycin alone and in combination with ivermectin in fighting against the symptoms of COVID-19. [The Professional Medical Journal, May 2021]
  13. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial [Journal of International Medical Research, April 2021]
  14. Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India [IJHCR, April 2021]
  15. Ivermectin and COVID-19 in Care Home: Case Report [Clin Med Journal, April 2021]
  16. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19 [Jama, March 2021]
  17. Safety and Efficacy of the Combined Use of Ivermectin, Dexamethasone, Enoxaparin and Aspirina against COVID-19 the I.D.E.A. Protocol [Journal of Clinical Trials, March 2021]
  19. Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study [MedRxIv, March 2021]
  20. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon [MDPI, March 2021]
  21. Use of Ivermectin as a Potential Chemoprophylaxis for COVID-19 in Egypt: A Randomised Clinical Trial [JCDR, February 2021]
  22. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients [EJMO, February 2021]
  23. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19 [Journal of Medical Virology, February 2021]
  24. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial [Science Direct, January 2021]
  25. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting [The Lancet, December 2020]
  26. Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis [Science Direct, December 2020]
  27. Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study [EJMED, December 2020]
  28. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness [Science Direct, November 2020]
  29. Study of the Efficacy and Safety of Topical Ivermectin + IotaCarrageenan in the Prophylaxis against COVID-19 in Health Personnel [Medical Press, November 2020]
  30. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study [Biomedical Research, August 2020]

Leave a Reply

Your email address will not be published. Required fields are marked *